FLEURY S.A. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 14.66 BRL | +4.64% |
|
+4.42% | -18.74% |
| Mar. 08 | Transcript : Fleury S.A., Q4 2023 Earnings Call, Mar 08, 2024 | |
| Mar. 07 | Fleury S.A. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 | CI |
| Sales 2024 * | 7.8B 1.52B | Sales 2025 * | 8.37B 1.64B | Capitalization | 7.99B 1.56B |
|---|---|---|---|---|---|
| Net income 2024 * | 637M 125M | Net income 2025 * | 795M 155M | EV / Sales 2024 * | 1.47 x |
| Net Debt 2024 * | 3.44B 672M | Net Debt 2025 * | 3.06B 599M | EV / Sales 2025 * | 1.32 x |
| P/E ratio 2024 * |
12.7
x | P/E ratio 2025 * |
10.2
x | Employees | 27,300 |
| Yield 2024 * |
2.33% | Yield 2025 * |
5.3% | Free-Float | 43.97% |
More Fundamentals
* Assessed data
More news
Latest transcript on Fleury S.A.
More press releases
| 1 day | +4.64% | ||
| 1 week | +4.42% | ||
| Current month | -2.27% | ||
| 1 month | -2.14% | ||
| 3 months | -11.10% | ||
| 6 months | -5.36% | ||
| Current year | -18.74% |
1 week
13.87
14.89
1 month
13.6915.15
Current year
13.6918.08
1 year
13.4318.96
3 years
12.8926.55
5 years
12.8932.47
10 years
6.1032.47
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 54 | 00-12-31 | |
| Director of Finance/CFO | 63 | 21-07-22 | |
| Chief Tech/Sci/R&D Officer | 48 | 06-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 72 | - | |
| Director/Board Member | 78 | 13-04-08 | |
João Teixeira
BRD | Director/Board Member | 57 | 21-04-29 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.43% | 2 M€ | -14.14% | ||
| 0.24% | 15 M€ | -3.58% | ||
| 0.02% | 4 M€ | -4.41% | - | |
| 0.01% | 117 M€ | +1.21% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 14.66 | +4.64% | 662 500 |
| 24-04-25 | 14.66 | +0.89% | 1,734,000 |
| 24-04-24 | 14.53 | -1.29% | 3,007,400 |
| 24-04-23 | 14.72 | +5.07% | 11,137,400 |
| 24-04-22 | 14.01 | -0.21% | 3,185,300 |
Delayed Quote Sao Paulo, April 26, 2024 at 12:31 pm EDT
More quotes
Fleury S.A. specializes in clinical diagnosis, treatment and analysis services.
At the end of 2018, the group operated a network of 187 patient care centers and 23 hospital centers under Fleury, Weinmann, Clínica Felipe Mattoso, a +, Labs a + and Diagnoson a + brands.
Calendar
2024-05-08
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
A-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
10
Last Close Price
14.66
BRL
Average target price
19.9
BRL
Spread / Average Target
+35.74%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -18.74% | 1.55B | |
| -17.89% | 8.36B | |
| +40.06% | 3.6B | |
| -39.11% | 2.73B | |
| -8.06% | 2.47B | |
| -7.35% | 2.32B | |
| -11.59% | 1.77B | |
| -40.66% | 1.22B | |
| +7.56% | 1.09B | |
| -15.34% | 1.03B |
- Stock Market
- Equities
- FLRY3 Stock
